The FDA’s approval of Wegovy on June 4, 2021, ended a seven-year drought in new obesity treatments and set off a chain reaction that has reshaped how doctors, patients, and insurers think about excess ...

March 6 (Reuters) - The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from ...

After losing significant ground to rival Eli Lilly in the GLP-1 space over the past two years, Novo Nordisk is defending the one arena it now dominates — oral therapeutics. But with Lilly preparing to ...

In this week’s STATus Report, host Alex Hogan explains why weight loss pills were so much harder to develop than injectables.

A new oral version of the weight loss drug Wegovy has been approved by the FDA, offering a more affordable and accessible ...

Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

So many options. So much noise. Here's what to know about GLP-1s now.

Eli Lilly (LLY) files a China marketing application for the oral GLP-1 weight loss drug orforglipron and pledges a $3B ...

Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be ...

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.

The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from Eli Lilly and Novo ...